Insider buying last 90 days
$1.03Min 2 open-market purchases
| Filed | Insider | Type | Value |
|---|---|---|---|
| Aug 21 | Kurzius Lawrence Erik director | Purchase | $936K |
| Aug 18 | Shiv O'Neill GC AND CORP SEC | Purchase | $94K |
From Form 4 filings, dated to when each was filed.
Nov 13 close
Elanco's third-quarter results drove this week's move, with revenue up 11% to $1.265 billion and organic constant currency growth of 9%, led by demand for pet health products Zenrelia and Credelio Quattro and higher prices across the portfolio. The company raised its full-year outlook and reported net income of $18 million, a marked improvement from a loss a year earlier, while also lowering gross debt by $216 million in the quarter. Management has continued to discuss these results publicly, including at the UBS Global Healthcare Conference on 9 November.
Shares closed at $26.84, up 4.3% on the day, sitting above both the 50-day average of $23.19 and the 200-day average of $23.81, with one-month returns of 17.1% and one-year returns of 24.7%. The GekkoIndex reads 41.9, placing ELAN in the Distribution zone, down 8.8 points over five sessions. Price sits 16.7% above Gekko Fair Value of $23.00.
The next earnings date falls on 23 February 2027, outside a typical 20-trading-day holding window. Over the last 90 days, insiders made 3 open-market purchases totaling $1,139,293, and one trailblazer holder is recorded. Analyst coverage from 13 firms shows 11 buy and 2 hold ratings, with a consensus target of $30.23. Seasonality over the next 20 trading days has averaged -0.8% across 5 years, rising in 2 of them, a pattern worth noting against the stock's typical 20-day move of 7.5%.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Elanco Animal Health scores 3 supportive, 2 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed1 headwind
Averages disagree
Close $26.78 sits between the 50-day ($23.38) and 200-day ($23.86) averages, or the averages disagree.
See the chart45.8, Neutral
Reading 45.8 is in the Neutral zone.
See the GekkoIndex13.0% above
Price is 13% above Gekko Fair Value (more than 5% above).
See fair valueLeans bullish
Last 90 days: 2 open-market insider purchases.
See smart moneyReports in 100 days
Next report Feb 23, 2027, 100 days away — outside a typical 20-trading-day hold.
See earnings+0.2% on average
From this point in the calendar, the next 20 trading days averaged +0.2% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Elanco Animal Health closed at $26.78 on Nov 13, 2026, +21.5% over the past year, inside a 52-week range of $19.40 to $27.98.
Use the left and right arrow keys to read daily values.
Put ELAN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Elanco Animal Health develops, manufactures, and sells products aimed at keeping pets and farm animals healthy. For dogs and cats, its lineup covers preventive treatments against parasites like fleas, ticks, and worms, sold under names such as Seresto, Advantage, Advantix, and Advocate, alongside medicines for pain, joint disease, ear infections, heart problems, and skin conditions marketed as Galliprant and Claro.
On the livestock side, Elanco makes vaccines, antibiotics, and parasiticides for poultry and aquaculture operations, plus nutritional additives like enzymes, probiotics, and prebiotics meant to support growth and overall health. For cattle, dairy herds, and pigs, it offers vaccines, antibiotics, implants, and parasiticides, including well-known products like Rumensin and Baytril. These goods reach the market through independent distributors, veterinary practices, and a wide range of animal producers spanning dairy and cattle farms to poultry, swine, and aquaculture businesses.
The company was founded in 1954 and is headquartered in Greenfield, Indiana. Its shares trade on the NYSE under the ticker ELAN.
Elanco Animal Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 45.8, in the Neutral zone, up 0.3 points over five sessions.
Up 0.3 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 41 | −0.6% | +9.7% | ||
| Accumulation | 223 | +1.5% | +4.1% | ||
| Neutral (current zone) | 398 | +0.2% | −0.1% | ||
| Distribution | 39 | +0.7% | +4.5% | ||
| Selling | 1 | Too few readings yet | |||
Average ELAN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Elanco Animal Health trades 13.0% above Gekko Fair Value of $23.70, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Elanco Animal Health shares are worth, recalculated every trading day.
$23.70
Gekko Fair Value, Nov 14, 2026
13.0% Overvalued
At the end of Aug 2026 the price was 23.0% above the estimate.
Insiders filed 2 open-market purchases in Elanco Animal Health worth $1.03M, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
$1.03Min 2 open-market purchases
| Filed | Insider | Type | Value |
|---|---|---|---|
| Aug 21 | Kurzius Lawrence Erik director | Purchase | $936K |
| Aug 18 | Shiv O'Neill GC AND CORP SEC | Purchase | $94K |
From Form 4 filings, dated to when each was filed.
No trades in ELAN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Elanco Animal Health has been buying back its own shares.
From company filings.
1of the funds Gekko tracks holds ELAN.
Elanco Animal Health reports on Feb 23, 2027, before the open (100 days away), and beat the EPS estimate in 7 of its last 8 reports.
Feb 23, 2027
Expected before the open, 100 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $0.34 est $0.27 | $1.37B est $1.31B | −5.5% |
| May 6, 2026 | $0.40 est $0.34 | $1.37B est $1.28B | +4.4% |
| Feb 24, 2026 | $0.13 est $0.11 | $1.14B est $1.09B | +8.4% |
| Nov 5, 2025 | $0.19 est $0.13 | $1.14B est $1.09B | −4.4% |
| Aug 7, 2025 | $0.26 est $0.20 | $1.24B est $1.09B | +19.2% |
| May 7, 2025 | $0.37 est $0.30 | $1.19B est $1.18B | +29.1% |
| Feb 25, 2025 | $0.14 est $0.15 | $1.02B est $1.21B | +0.2% |
| Nov 7, 2024 | $0.13 est $0.12 | $1.03B est $1.01B | +9.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Elanco Animal Health is $31.00, +15.8% from the last close, from 11 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 11 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 9 | Piper Sandler | $30 | +12.0% |
| Nov 9 | J.P. Morgan | $35 | +30.7% |
| Nov 9 | UBS | $35 | +30.7% |
| Nov 9 | Stifel Nicolaus | $33 | +23.2% |
| Nov 9 | KeyBanc | $30 | +12.0% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Elanco Animal Health averaged +0.2% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.4% | 2 of 5 |
| Next 10 trading days | −1.9% | 2 of 5 |
| Next 15 trading days | −2.1% | 2 of 5 |
| Next 20 trading days | +0.2% | 3 of 5 |
| Next 30 trading days | +0.5% | 2 of 5 |
For scale, ELAN’s typical 20-trading-day move in either direction is about 7.5%.
Elanco Animal Health’s market cap is $13.39B and revenue of $5.15B over the last twelve months.
Coverage of Elanco Animal Health this week reads positive: 10 positive, 1 neutral and 0 negative headlines.
Elanco Animal Health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 19.9% below |
| GILDGilead Sciences | Neutral | 11.7% above |
| MRNAModerna | Neutral | 21.1% above |
| NTRANatera | Accumulation | 18.6% below |
| IQVIQVIA | Accumulation | 5.0% above |
| UTHRUnited Therapeutics | Neutral | 11.2% below |
A peer links to its own page where one exists.
Elanco Animal Health’s market cap is $13.39B at the Nov 13, 2026 close of $26.78, with 499.8M shares outstanding.
The consensus analyst 12-month price target for Elanco Animal Health is $31.00, +15.8% from the last close. Of the 11 firms that rated the stock in the last 90 days, 9 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Elanco Animal Health is overvalued: the Nov 13, 2026 close of $26.78 is 13.0% above Gekko Fair Value of $23.70. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Elanco Animal Health is expected to report on Feb 23, 2027, before the market opens (100 days away). Analysts expect earnings of $0.18 per share on revenue of $1.20B. Elanco Animal Health beat the earnings estimate in 7 of its last 8 reports, moving 10.1% on average across the report.
Elanco Animal Health’s 52-week high is $27.98 and its 52-week low is $19.40; it closed at $26.78 on Nov 13, 2026, +21.5% over the past year. Over the last five years the shares peaked at $33.20 on Nov 18, 2021.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (smart money, earnings risk and seasonality), 2 as mixed (trend and gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.